




























Abstract. Recently, a functional T to G polymorphism at
nucleotide 309 in the promoter region of the MDM2 gene (rs:
2279744, SNP 309) has been identified. This polymorphism
has an impact on the expression of the MDM2 gene, which is
a key negative regulator of the tumor suppressor molecule p53.
The effect of T309G polymorphism of the MDM2 gene on
bladder cancer susceptibility was investigated in a case-control
study of 75 bladder cancer patients and 103 controls from
Turkey. The G/G genotype exhibited an increased risk of 2.68
(95% CI, 1.34-5.40) for bladder cancer compared with the
combination of low-risk genotypes T/T and T/G at this locus.
These results show an association between MDM2 T309G
polymorphism and bladder cancer in our study group. To the
best of our knowledge, this is the first study reporting that
MDM2 T309G polymorphism may be a potential genetic
susceptibility factor for bladder cancer.
Bladder cancer is a major cause of morbidity and mortality.
In the Turkish population, it is the third most common
cancer in men and the eighth in women (1). Although
multiple environmental and host genetic factors are known
to be important in bladder cancer development, the exact
molecular mechanisms of genetic susceptibility and
molecular changes during malignant transformation are still
under investigation.
Recently, a functional T to G polymorphism at nucleotide
309 in the promoter region of the MDM2 gene (rs: 2279744)
has been identified (2). We hypothesized that this gene
polymorphism might be a critical predisposition factor for
bladder cancer, as the MDM2 molecule is an important
player in bladder cancer pathogenesis, evidenced by its over-
expression in 30% of urothelial carcinoma (3). This
oncoprotein attenuates p53 activity by promoting ubiquitin-
mediated degradation (4). In addition to functional
inactivation by MDM2, structural TP53 mutations have been
observed in 50% of urothelial cancer and these mutations
were associated with poor prognosis, advanced stage and
higher grade of the bladder cancer (3).
MDM2 T309G polymorphism is a functional polymorphism
having an impact on the p53 protein level in the cell. The G
allele confers an increased binding affinity to the Sp1
transcriptional activator, hence increased transcription of the
MDM2 gene. Eventually, the relative increase in the level of
MDM2 protein causes a relative decrease in the level of the
p53 protein (2).
It is recognized that host genetic factors modifying the
genotoxicity of carcinogens are important for the genetic
susceptibility to bladder cancer. For example, gene
polymorphisms decreasing the carcinogen detoxification
activity of glutathione S-tranferases and N-acetyl
transferases are established predisposition factors for this
cancer (5). The p53 molecule is considered to be the
guardian of the genome, since it plays a vital part in various
antineoplastic mechanisms such as cell cycle arrest,
senescence and apoptosis, preventing the carcinogenic effect
of mutagens (6). Therefore, it is conceivable that MDM2
SNP 309, which has an effect on the level of p53, may also
be a genetic predisposition factor for bladder cancer. 
In order to investigate the role of MDM2 T309G
polymorphism in bladder cancer, a case-control study was
performed with 75 patients and 103 controls. Our results
indicated an association between bladder cancer risk and
MDM2 SNP309 polymorphism in the group indicated.
Patients and Methods
Peripheral blood samples were collected from 75 bladder cancer
patients and 103 age-matched controls (non-cancer) diagnosed at
Hacettepe University Medical School, and Ankara Numune
Hospital, Turkey. The mean age of the bladder cancer patients was
59.87 years, with a standard deviation of 12.54, range 25-87; the
mean age of the control group was 59.33 years, with a standard
deviation of 13.58, range 23-79. Genomic DNA was isolated from
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200 Ìl blood by standard phenol-chloroform extraction. MDM2
T309G polymorphism was determined by polymerase chain reaction
(PCR) and restriction digestion. The PCR amplification was carried
out using primers: MDM2F (5’-GCTTTGCGGAGGTTTTGTT-3’)
and MDM2R (5’-TCAAGTTCAGACACGTTCCG-3’). After
confirming the presence of the 304-bp amplicon on 2% agarose test
gel, the PCR products were digested with MspA1I and
electrophoresed in 3% agarose gel for SNP 309 genotyping. The T
allele had a constitutional restriction site, which also served as an
internal control for restriction digestion. The G allele had an
additional restriction site to the constitutional restriction site. After
digestion, T allele yielded two fragments (193 bp and 111 bp), where
as the G allele yielded three fragments (147 bp, 111 bp and 46 bp)
(Figure 1).
The G/G genotype was defined as the risk group for statistical
analysis. Odds ratio (OD) tests with 95% confidence interval (CI)
and ¯2 analysis were performed with the GraphPad Prism4
statistical software.
Results and Discussion 
The genotype frequencies of MDM2 T309G polymorphism
in the bladder cancer patients and control groups are
summarized in Table I. The genotype frequency values for
the control group closely resembled the results from other
Caucasian populations (7-9) and were in Hardy Weinberg
equilibrium. The comparison of the high-risk genotype
(G/G) with the combination of the two low-risk alleles (G/T
and T/T) revealed that the G/G genotype conferred a risk of
2.68 (95% CI 1.34-5.40) relative to the low-risk genotypes
(Table I). The G allele frequency in the patient group was
0.58 (T allele: 0.42), the control group it was 0.44 (T allele:
0.56). There was a significant difference between the allelic
frequencies of the control (n=150 alleles) and patient groups
(n=206 alleles) (¯2: 6.76, df: 1, p=0.0093). Odds ratio
analysis revealed that the G allele resulted in a 1.72-fold risk
increase (95% CI 1.14-2.60) compared to the T allele.
After the initial discovery of MDM2 T309G polymorphism,
several reports were published with discordant results
regarding the impact of this polymorphism on cancer risk. In
two separate studies, it was shown that G/G genotype caused a
reduction in the age of onset of cancer in Li-Fraumeni
syndrome patients (2, 10). However, no age of onset reduction
was observed for Lynch syndrome (7). The case-control studies
on colorectal cancer (9), squamous cell carcinoma of the head
and neck (9), uterine leiomyosarcoma (9), breast (8, 11) and
ovarian cancer (8) did not show an association. Interestingly,
two lung cancer studies in the Chinese population reported
discordant results: in one study an association was observed
(12), while in the other it was not (13). 
Issues with sampling and population stratification have
always been cited for the lack of reproducibility between
different case-control studies (14), but p53-related factors
might also have contributed to such problems. It is intriguing
that MDM2 T309G polymorphism had an impact on a
hereditary cancer syndrome (2, 10) characterized by germ
line p53 mutations (i.e., Li-Fraumeni syndrome), but had no
effect on another hereditary cancer such as lynch syndrome
(7) with relatively rare somatic p53 mutations (15). 
In conclusion, this study showed an association between
MDM2 T309G polymorphism and bladder cancer in the
Turkish population. The small sample size was a limitation
of the study and the results should definitely be validated
on larger bladder cancer cohorts in different populations.
That said, to our knowledge, the study is the first study to
indicate that MDM2 T309G polymorphism could be a
potential genetic susceptibility factor for bladder cancer.
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111 bp). 97-571 and 97-572 are examples of G/T heterozygotes; 97-578
and 97-601 are G/G homozygotes; and 97-603 is a T/T homozygote. M is
the pUC mix 8 (MBI Fermentas).
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